Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study
Nephrotoxicity is the major limitation to cisplatin therapy for solid tumors. We aimed at evaluating whether early increases in serum/urine levels of neutrophil gelatinase-associated lipocalin (NGAL), a biomarker of tubular damage and regeneration, predict cisplatin-induced acute kidney injury (AKI)...
Saved in:
Published in | Nephron Vol. 115; no. 2; p. c154 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
S. Karger AG
01.06.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Nephrotoxicity is the major limitation to cisplatin therapy for solid tumors. We aimed at evaluating whether early increases in serum/urine levels of neutrophil gelatinase-associated lipocalin (NGAL), a biomarker of tubular damage and regeneration, predict cisplatin-induced acute kidney injury (AKI).
We compared changes in serum creatinine and serum/urine NGAL levels (ELISA assay) at 1 and 4 h and 1, 2, 3, 7 and 15 days after cisplatin infusion (70-80 mg/m(2)) versus baseline in 12 consecutive cancer patients (cases) with AKI (>25% serum creatinine increase vs. baseline) and 12 consecutive controls without AKI.
Baseline characteristics and posttreatment serum NGAL levels were similar in both groups. Urinary NGAL levels increased significantly more in cases than in controls at 1, 2, 3 and 15 days after cisplatin. The NGAL increase preceded AKI by 4.5 days and the NGAL increase at day 2 after cisplatin independently predicted AKI (p < 0.05). Six cases with residual kidney dysfunction at 15 days showed a trend to earlier and higher increase in urinary NGAL levels compared to cases with renal function recovery.
An early increase in urinary NGAL excretion may help in identifying patients at risk of cisplatin-induced AKI who might benefit from innovative treatments to prevent cisplatin nephrotoxicity. |
---|---|
AbstractList | Background/Aims: Nephrotoxicity is the major limitation to cisplatin therapy for solid tumors. We aimed at evaluating whether early increases in serum/urine levels of neutrophil gelatinase-associated lipocalin (NGAL), a biomarker of tubular damage and regeneration, predict cisplatin-induced acute kidney injury (AKI). Methods: We compared changes in serum creatinine and serum/urine NGAL levels (ELISA assay) at 1 and 4 h and 1, 2, 3, 7 and 15 days after cisplatin infusion (70-80 mg/m2) versus baseline in 12 consecutive cancer patients (cases) with AKI (>25% serum creatinine increase vs. baseline) and 12 consecutive controls without AKI. Results: Baseline characteristics and posttreatment serum NGAL levels were similar in both groups. Urinary NGAL levels increased significantly more in cases than in controls at 1, 2, 3 and 15 days after cisplatin. The NGAL increase preceded AKI by 4.5 days and the NGAL increase at day 2 after cisplatin independently predicted AKI (p < 0.05). Six cases with residual kidney dysfunction at 15 days showed a trend to earlier and higher increase in urinary NGAL levels compared to cases with renal function recovery. Conclusion: An early increase in urinary NGAL excretion may help in identifying patients at risk of cisplatin-induced AKI who might benefit from innovative treatments to prevent cisplatin nephrotoxicity. Copyright © 2010 S. Karger AG, Basel [PUBLICATION ABSTRACT] Nephrotoxicity is the major limitation to cisplatin therapy for solid tumors. We aimed at evaluating whether early increases in serum/urine levels of neutrophil gelatinase-associated lipocalin (NGAL), a biomarker of tubular damage and regeneration, predict cisplatin-induced acute kidney injury (AKI). We compared changes in serum creatinine and serum/urine NGAL levels (ELISA assay) at 1 and 4 h and 1, 2, 3, 7 and 15 days after cisplatin infusion (70-80 mg/m(2)) versus baseline in 12 consecutive cancer patients (cases) with AKI (>25% serum creatinine increase vs. baseline) and 12 consecutive controls without AKI. Baseline characteristics and posttreatment serum NGAL levels were similar in both groups. Urinary NGAL levels increased significantly more in cases than in controls at 1, 2, 3 and 15 days after cisplatin. The NGAL increase preceded AKI by 4.5 days and the NGAL increase at day 2 after cisplatin independently predicted AKI (p < 0.05). Six cases with residual kidney dysfunction at 15 days showed a trend to earlier and higher increase in urinary NGAL levels compared to cases with renal function recovery. An early increase in urinary NGAL excretion may help in identifying patients at risk of cisplatin-induced AKI who might benefit from innovative treatments to prevent cisplatin nephrotoxicity. |
Author | de Leon, Felipe Rodríguez Ruggenenti, Piero Remuzzi, Giuseppe Gaspari, Flavio Cravedi, Paolo Perico, Norberto Ferrari, Silvia Mandalà, Mario Labianca, Roberto Stucchi, Nadia |
Author_xml | – sequence: 1 givenname: Flavio surname: Gaspari fullname: Gaspari, Flavio organization: Department of Medicine and Transplantation, Ospedali Riuniti, Mario Negri Institute for Pharmacological Research, Bergamo, Italy – sequence: 2 givenname: Paolo surname: Cravedi fullname: Cravedi, Paolo – sequence: 3 givenname: Mario surname: Mandalà fullname: Mandalà, Mario – sequence: 4 givenname: Norberto surname: Perico fullname: Perico, Norberto – sequence: 5 givenname: Felipe Rodríguez surname: de Leon fullname: de Leon, Felipe Rodríguez – sequence: 6 givenname: Nadia surname: Stucchi fullname: Stucchi, Nadia – sequence: 7 givenname: Silvia surname: Ferrari fullname: Ferrari, Silvia – sequence: 8 givenname: Roberto surname: Labianca fullname: Labianca, Roberto – sequence: 9 givenname: Giuseppe surname: Remuzzi fullname: Remuzzi, Giuseppe – sequence: 10 givenname: Piero surname: Ruggenenti fullname: Ruggenenti, Piero |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20407275$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kMlOAzEQRC0URBY48API4j7QtmflhiI2KRIc4Bx57E5wmNjD2EbkT_hcDIRT16FeVaumZGSdRUJOGVwwVjSXACAYr6vmgExYWULGGYPRXtesYGMy9X4DwDmD5oiMOeRQ8aqYkK-nAbVRwdg1Vcb3nUwyM1ZHhZpKFQPSN6Mt7qixmzjsaLujcTBWJmkxhsH1r6aja_wlpcdMeu-UkSHxnemdkp2xFD_VgME4e0Ul7U3nAu0H53tM1R9I1Q-onE1xHfUh6t0xOVzJzuPJ_s7Iy-3N8_w-WzzePcyvF5nKBYSsAqx5oxSIMm9EjYpxlLpYQctKBmLFJBeyFW2et7LSrWxkjYUuAQVDnWMjZuT8Lze98x7Rh-XGxcGmymXBqgIEL4tkOtubYrtFvewHs00DLP93FN9DXHnL |
CODEN | NPRNAY |
CitedBy_id | crossref_primary_10_1177_2054358117690338 crossref_primary_10_7314_APJCP_2015_16_2_407 crossref_primary_10_1155_2011_328120 crossref_primary_10_1111_bcp_12601 crossref_primary_10_1093_ndt_gfx002 crossref_primary_10_1128_AAC_01079_15 crossref_primary_10_1186_s12882_022_02760_4 crossref_primary_10_1038_ki_2013_489 crossref_primary_10_34067_KID_0004802021 crossref_primary_10_1016_j_kjms_2012_10_004 crossref_primary_10_1007_s10157_023_02415_0 crossref_primary_10_1097_MNH_0000000000000481 crossref_primary_10_1093_ndt_gfs556 crossref_primary_10_1152_ajprenal_00165_2016 crossref_primary_10_3390_ijms25021074 crossref_primary_10_5402_2013_394582 crossref_primary_10_1002_pbc_25137 crossref_primary_10_1177_1535370217745302 crossref_primary_10_1152_ajprenal_00688_2016 crossref_primary_10_1097_MOH_0b013e3283411517 crossref_primary_10_33549_physiolres_934212 crossref_primary_10_1002_jat_3780 crossref_primary_10_1007_s00467_012_2171_3 crossref_primary_10_1186_1471_2369_13_25 crossref_primary_10_1186_s13063_015_0772_4 crossref_primary_10_1111_cts_12547 crossref_primary_10_3389_fonc_2023_1331671 crossref_primary_10_1016_j_bcp_2019_113664 crossref_primary_10_1002_ptr_5345 crossref_primary_10_2217_bmm_13_51 crossref_primary_10_1097_MOP_0b013e328343f4dd crossref_primary_10_7314_APJCP_2013_14_2_1111 crossref_primary_10_1016_j_ejim_2016_12_001 crossref_primary_10_1016_j_nephro_2012_03_006 crossref_primary_10_1016_j_jpeds_2017_06_045 crossref_primary_10_30895_2312_7821_2021_9_4_173_184 crossref_primary_10_5812_numonthly_87523 crossref_primary_10_1007_s10157_017_1448_z crossref_primary_10_1681_ASN_2017111207 crossref_primary_10_1016_j_ejim_2011_02_002 crossref_primary_10_1016_j_ccc_2010_12_003 crossref_primary_10_1021_acs_jproteome_7b00014 crossref_primary_10_1155_2012_563404 crossref_primary_10_1186_s12882_018_1022_2 crossref_primary_10_3390_ijms23052638 crossref_primary_10_17826_cumj_1400660 crossref_primary_10_1097_ALN_0000000000000446 crossref_primary_10_1111_ctr_12271 crossref_primary_10_1007_s10330_010_0708_0 crossref_primary_10_3810_pgm_2013_11_2715 crossref_primary_10_1177_1078155220901756 crossref_primary_10_3727_096368915X689622 crossref_primary_10_1080_0886022X_2016_1227917 crossref_primary_10_2217_bmm_10_115 crossref_primary_10_1007_s40264_017_0565_7 crossref_primary_10_1038_bjc_2016_160 crossref_primary_10_1093_jac_dkw351 crossref_primary_10_1097_MCC_0000000000000777 crossref_primary_10_3390_ijms20123103 crossref_primary_10_1371_journal_pone_0105988 crossref_primary_10_1007_s11255_017_1556_4 crossref_primary_10_1093_jjco_hyw004 crossref_primary_10_3947_ic_2018_50_2_128 crossref_primary_10_1007_s00280_015_2880_y crossref_primary_10_1371_journal_pone_0110527 crossref_primary_10_17650_1726_9784_2015_14_3_3_18 crossref_primary_10_3109_0886022X_2014_996843 |
ContentType | Journal Article |
Copyright | Copyright 2010 S. Karger AG, Basel. Copyright (c) 2010 S. Karger AG, Basel |
Copyright_xml | – notice: Copyright 2010 S. Karger AG, Basel. – notice: Copyright (c) 2010 S. Karger AG, Basel |
DBID | CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PQEST PQQKQ PQUKI S0X |
DOI | 10.1159/000312879 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition SIRS Editorial |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) SIRS Editorial ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts Immunology Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
DatabaseTitleList | SIRS Editorial MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection (Proquest) url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1660-2110 2235-3186 |
ExternalDocumentID | 2065297071 20407275 |
Genre | Journal Article Comparative Study |
GroupedDBID | --- 0R~ 0~B 123 36B 3O. 4.4 53G 8UI AAYIC ACGFS AEYAO AFJJK ALDHI ALMA_UNASSIGNED_HOLDINGS BENPR CAG CGR COF CS3 CUY CVF CYUIP DU5 E0A EBS ECM EIF EJD EMB FB. HZ~ IY7 N9A NPM O1H O9- RKO UJ6 .55 29M 3V. 5RE 7T5 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABJNI ABOCM ABUWG ACPRK ADFRT AFKRA AHMBA ALIPV BPHCQ CCPQU F5P FYUFA H94 K9. L7B M1P PQEST PQQKQ PQUKI S0X X7M |
ID | FETCH-LOGICAL-c430t-70e829cc0364938ec12ead5f0b16103f1a23ab3b44ba7dba9a8e5d60e31ed4e93 |
IEDL.DBID | BENPR |
ISSN | 1660-8151 |
IngestDate | Wed Aug 28 13:35:11 EDT 2024 Thu May 23 23:17:06 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Copyright 2010 S. Karger AG, Basel. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c430t-70e829cc0364938ec12ead5f0b16103f1a23ab3b44ba7dba9a8e5d60e31ed4e93 |
PMID | 20407275 |
PQID | 517503265 |
PQPubID | 41086 |
ParticipantIDs | proquest_journals_517503265 pubmed_primary_20407275 |
PublicationCentury | 2000 |
PublicationDate | 2010-06-00 |
PublicationDateYYYYMMDD | 2010-06-01 |
PublicationDate_xml | – month: 06 year: 2010 text: 2010-06-00 |
PublicationDecade | 2010 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Nephron |
PublicationTitleAlternate | Nephron Clin Pract |
PublicationYear | 2010 |
Publisher | S. Karger AG |
Publisher_xml | – name: S. Karger AG |
SSID | ssj0022109 ssj0014980 |
Score | 2.2535977 |
Snippet | Nephrotoxicity is the major limitation to cisplatin therapy for solid tumors. We aimed at evaluating whether early increases in serum/urine levels of... Background/Aims: Nephrotoxicity is the major limitation to cisplatin therapy for solid tumors. We aimed at evaluating whether early increases in serum/urine... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | c154 |
SubjectTerms | Acute Kidney Injury - chemically induced Acute Kidney Injury - diagnosis Acute Kidney Injury - urine Acute-Phase Proteins - urine Aged Biomarkers - urine Case-Control Studies Cisplatin - adverse effects Female Follow-Up Studies Humans Lipocalin-2 Lipocalins - urine Male Middle Aged Pilot Projects Predictive Value of Tests Prospective Studies Proto-Oncogene Proteins - urine |
Title | Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20407275 https://www.proquest.com/docview/517503265/abstract/ |
Volume | 115 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9swDBbaBCh6GfZq18cCHXoVIluSbe1SpEHabmsCY1iA3AJJVlAXhew5DtD8k_7ciX702JsNmBdSIml-H0mErqjW2me6mmRUKsKVskQLZQjXEuBDnaiGTThfRPdL_mslVgforu-FAVpl7xMbR50VBmrkYxEA4hZGYqw0FAFMPb4u_xFYHwUwa7dL4xANw4ADXju8mS3SP2-AApfNErUgiihJfJTrhgz5YA69DMx76fidJLMJNrcf0YcuS8ST1qyf0IF1n9HRvMPBv6DXtIJnoCzjab4tgdDmCKzhMDbDE7OrLf6dZ87u8U_35NWG9R4vq6b3Fi_srq6K8jF_xncNFc75SEZ6O3n5h7yECJc7PHsx0OVYuB94gtP8uahxWhV9dyaeguC0JbtjYCTuv6Ll7ezv9J50OxaI4YzWJKY2CaUxAEdKllgThP5siQ3VPhWkbBOokCnNNOdaxZlWUiVWZBG1LLAZt5KdoIErnP2GMAzCiYWSgY-J_nOZ-D-xkEVCbkIdSCvO0EWv3nV3UbbrN7OeodNW4-uyHbOxDikMb4vF-btyF-i4BfShMHKJBnW1s999nlDrETqMV_GoOwn-bZHO_wN648FS |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,33779,43345,43840,74102,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NT-MwELX4kIALAnaXb_BhrxZObCcxF1RVQIG26oFKvUW242qzQk5IU4n-E34uniTlyC0H-zLjzBv7vZlB6C_VWvtMV5OMSkW4UpZooQzhWgJ9qBPVqAlH42gw5c8zMeu0OYtOVrmOiU2gzgoDb-Q3IgDGLYzEXflOYGgUkKvdBI1NtM0Z46Doi2ff9y2f-zeD04IooiTxyNY1FvIADvULzEfm-IfEsgGYhwO032WGuNe68hBtWHeEdkYd9_0LfU4q-AaZMu7nixJEbI7A6A1jM9wzy9rilzxzdoWf3H9vKqxXeFo19bZ4bJd1VZT_8jf82MjfnEcvsvaN3z_MS0C13OH7DwOVjYW7xT08yd-KGk-qYl2Rifuwsd8K3DGoEFe_0fTh_rU_IN1cBWI4ozWJqU1CaQxQkJIl1gShP09iTrVP_yibBypkSjPNuVZxppVUiRVZRC0LbMatZH_QliucPUEYmt_EQsnA46BfLhN_-wpZJOQ81IG04hSdr82bdj_HIv125Sk6bi2elm1rjTSk0LAtFmc_7rtGu4PX0TAdPo1fztFeS-jDw8gF2qqrpb30eUKtr5rT8AUD7r0s |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9swDBXaFCh6GbquH1nbTYddhcqWZVu7DEGaLG3SIIcGyM2QZAV1Ucie4wDLP9nPnWgrPfbmg3QhaT5SfCQR-kGVUi7SVSSnQpJISkMUl5pESkD5UKWyZRM-zePJMnpc8ZUfKbTxtMq9T2wddV5qeCO_4wFU3MKY3609K2JxP_5V_SGwQAoKrX6bxiE6ciBJYZlBsnrPvVwe0C5RC-KYktShnB8y5MAcehmY89LJB0FmCzbjU_TJR4l40Kn1Mzow9gwdP_k6-Bf0b1HDN1CW8bDYVEBoswTWcGiT44HeNgZPi9yaHX6wr05sWO3wsm57b_HcbJu6rF6KN_y7pcJZh2Rkryd3f1ZUgHCFxaO_GrocS_sTD_CieCsbvKjLfXcmHsLFYUd2x8BI3J2j5Xj0PJwQv2OB6IjRhiTUpKHQGsqRgqVGB6GzLb6myoWClK0DGTKpmIoiJZNcSSFTw_OYGhaYPDKCXaCeLa25QhgG4SRcisBhojsuUpeJhSzmYh2qQBjeR9d78Wb-R9lk72rto8tO4lnVjdnIQgrD2xL-9cN739GxM4Rs9jCfXqOTrrYPbyQ3qNfUW3PrQoZGfWuN4T-OJsFY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predicting+Cisplatin-Induced+Acute+Kidney+Injury+by+Urinary+Neutrophil+Gelatinase-Associated+Lipocalin+Excretion%3A+A+Pilot+Prospective+Case-Control+Study&rft.jtitle=Nephron&rft.au=Gaspari%2C+Flavio&rft.au=Cravedi%2C+Paolo&rft.au=Mandal%C3%A0%2C+Mario&rft.au=Perico%2C+Norberto&rft.date=2010-06-01&rft.pub=S.+Karger+AG&rft.issn=1660-8151&rft.eissn=2235-3186&rft.volume=115&rft.issue=2&rft.spage=c154&rft_id=info:doi/10.1159%2F000312879&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=2065297071 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1660-8151&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1660-8151&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1660-8151&client=summon |